Reflecting on his three years at the helm of the Medicines Patent Pool (MPP), executive director Greg Perry has good reason to be proud. By negotiating voluntary licences with all the major originators and intellectual-property (IP) holders in the antiretrovirals sector, the MPP has already saved healthcare authorities around the world well over US$100 million, and savings of around US$1.5 billion are anticipated up to 2028. And with a remit recently broadened to cover hepatitis C and tuberculosis treatments, the organisation is in prime position to fulfil a major public-health role.

Read full aricle here.